Iron chelation

Phase 2Small molecule

UUniversity of Michigan Rogel Cancer Center

Iron chelation is one of 25 small molecule programs targeting Stem Cell Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stem Cell TransplantRecruiting

Stem Cell TransplantPhase 2

Recruiting

Competition

Competitive Landscape

28 competitors in Stem Cell Transplant

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 3

39 2

Cellcept

Roche

Phase 3

26 3

Alkeran

AApotex Inc.

Phase 3

25 4

Busulfex

Akero Therapeutics

Phase 2

35 5

Fludara

Sanofi

Phase 2

12 6

Prograf

VVeloxis Pharmaceuticals

Phase 2

29 7

Cytoxan

BBaxter Healthcare Corporation

Phase 2

25 8

Cytosar

Teva

Phase 2

6 9

Medrol

Pfizer

Phase 2

5 10

Neupogen

EEastern Cooperative Oncology Group

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 2Recruiting

Stem Cell Transplant

NCT06784336

Clinical

Trials by Indication[1]

Stem Cell Transplant1 trial

Phase II Multi-center Study of Resistant Potato Starch Plus Deferasirox to Improve Outcomes in Patients Undergoing Allogeneic Stem Cell Transplantation

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT06784336·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Iron chelation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Iron chelation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Iron chelation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan Rogel Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Michigan Rogel Cancer Center

Iron chelation

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Trials by Indication[1]

Stem Cell Transplant1 trial

References

Drug Info

Quick Facts

Related News